文献速递胸部肿瘤放疗放疗物理与技术

可手术早期肺癌的质子和碳离子放疗:一项前瞻性全国注册研究

Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry.
PubMed 文献 · Radiother Oncol · 2024-06-18

这项多中心全国前瞻性队列研究纳入274例可手术早期肺癌患者,按统一治疗政策接受质子或碳离子放疗。3年无进展生存率为80.5%,总生存率为92.5%,3级或更严重治疗相关毒性见于4例(1.5%)。作者认为质子和碳离子束治疗是可替代根治性手术的可行选择。

要点

  • 274例可手术早期肺癌患者接受质子或碳离子放疗,3年无进展生存率80.5%、总生存率92.5%。
  • 3级或更严重治疗相关毒性见于4例(1.5%)。
  • 病理确认和临床分期与无进展生存显著相关,肿瘤位置和粒子类型与之无关。

核心结论

  • 可手术早期肺癌的粒子治疗在各亚组均获得优异的3年总生存和无进展生存。
  • 在此疾病背景下,质子束和碳离子束治疗是根治性手术的可行替代方案。

研究设计与样本

  • 多中心全国前瞻性队列研究,纳入可手术早期肺癌患者,按统一治疗政策规定的方案行质子或碳离子放疗。
  • 共274例患者入组并纳入疗效和安全性分析。

主要发现

  • 最常见的肿瘤类型为腺癌(44%),105例(38%)未获组织学确认或为临床诊断。
  • 274例中250例(91%)肿瘤位于外周,138例(50%)接受质子放疗、136例(50%)接受碳离子放疗。
  • 全部删失患者的中位随访时间为42.8个月(IQR 36.7-49.0)。
  • 3级或更严重治疗相关毒性见于4例(1.5%)。
  • 3年无进展生存率为80.5%(95% CI:75.7%-85.5%),总生存率为92.5%(95% CI:89.3%-95.8%)。

关键数值与推荐

  • 病理确认和临床分期是与无进展生存显著相关的因素,肿瘤位置和粒子类型则不是。
  • 临床分期与总生存显著相关,病理确认、肿瘤位置和粒子类型与总生存无显著相关。

临床怎么用

  • 作者认为,在此疾病背景下,质子束和碳离子束治疗是根治性手术的可行替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To investigate the toxicity and survival outcomes of proton and carbon ion radiotherapy for patients with operable early-stage lung cancer who are eligible for lobectomy. MATERIALS AND METHODS: This multicenter nationwide prospective cohort study included patients with operable early-stage lung cancer. Proton and carbon ion radiotherapy was performed according to the schedule stipulated in the unified treatment policy. Progression-free survival (PFS), overall survival (OS) and treatment-related toxicities were evaluated. RESULTS: A total of 274 patients were enrolled and included in efficacy and safety analyses. The most common tumor type was adenocarcinoma (44 %), while 105 cases (38 %) were not histologically confirmed or diagnosed clinically. Overall, 250 (91 %) of the 274 patients had tumors that were peripherally situated, while 138 (50 %) and 136 (50 %) patients were treated by proton and carbon ion radiotherapy, respectively. The median follow-up time for all censored patients was 42.8 months (IQR 36.7-49.0). Grade 3 or severe treatment-related toxicity was observed in 4 cases (1.5 %). Three-year PFS was 80.5 % (95 % CI: 75.7 %-85.5 %) and OS was 92.5 % (95 % CI: 89.3 %-95.8 %). Pathological confirmation and clinical stage were factors significantly associated with PFS, while tumor location and particle-ion type were not. Meanwhile, clinical stage was significantly associated with OS, but pathological confirmation, tumor location, and particle-ion type were not. CONCLUSIONS: Particle therapy for operable early-stage lung cancer resulted in excellent 3-year OS and PFS in each subset. In this disease context, proton and carbon ion beam therapies are feasible alternatives to curative surgery.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Harada H, Suefuji H, Mori K, et al. Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry. Radiother Oncol. 2024. PMID: 38901770. doi:10.1016/j.radonc.2024.110385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。